Patheon in Pact with AdventRx

AdventRx Pharmaceuticals has entered into a multi-year agreement with Patheon under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the Phase III study of ANX-188 that AdventRx plans to initiate this year.

ANX-188 is a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease, according to an AdventRx statement.

“This agreement is another step toward initiating the phase 3 study of ANX-188 in patients with sickle cell disease,” said Brian M. Culley, chief executive officer of AdventRx. “Patheon is a global contract manufacturer that serves more than 300 customers, including many of the world’s largest pharmaceutical and biotechnology companies. I am confident in their manufacturing expertise, experienced staff and world-class facilities and pleased to partner with them for the manufacture of ANX-188 clinical trial material.”